BerGenBio ASA: Results for the Second Quarter and First Half 2018
· Encouraging clinical data emerging from several phase II trials with highly selective AXL inhibitor bemcentinib (BGB324) · Advanced lung cancer (NSCLC): First stage fully recruited, and first efficacy endpoint met in phase II trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® · Advanced leukaemia (AML/MDS): Encouraging bemcentinib single agent activity in hard to treat relapsed / refractory (R/R) leukaemia · Pipeline update: AXL antibody preparing for Phase I clinical trialBergen, Norway, 21 August 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage